Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) – preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial

BACKGROUND: Neuroprotection and promotion of remyelination represent important therapeutic gaps in multiple sclerosis (MS). Acute optic neuritis (ON) is a frequent MS manifestation. Based on the presence and properties of sphingosine-1-phosphate receptors (S1PR) on astrocytes and oligodendrocytes, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Albert, Christian, Mikolajczak, Janine, Liekfeld, Anja, Piper, Sophie K., Scheel, Michael, Zimmermann, Hanna G., Nowak, Claus, Dörr, Jan, Bellmann-Strobl, Judith, Chien, Claudia, Brandt, Alexander U., Paul, Friedemann, Hoffmann, Olaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052969/
https://www.ncbi.nlm.nih.gov/pubmed/32126977
http://dx.doi.org/10.1186/s12883-020-01645-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052969/
https://www.ncbi.nlm.nih.gov/pubmed/32126977
http://dx.doi.org/10.1186/s12883-020-01645-z

Ejemplares similares